Upon completion of the activity, participants should be able to: 1. Explain to patients and peers the scientific rationale and empirical data with biosimilars that make them as safe and effective as their biologic originators for rheumatologic conditions 2. Explain the circumstances under which it is appropriate to initiate or switch a patient with rheumatoid arthritis to a biosimilar